InsidersTradesSigma
Follow the Merrimack Pharmaceuticals INC stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Merrimack Pharmaceuticals INC has logged 63 public disclosures. The latest transaction was filed on 28 December 2023 (Acquisition). Among the most active insiders: CROCKER GARY L. All data is accessible without an account.
63
Insider Decl.
n/a
Thresholds
€10m
59 ops.
Buy Volume
€3,391
2 ops.
Sell Volume
43Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 28 December 2023
Declarations63 total
48,693 shares@ US$13.156.6% of flowCommon StockSEC:0000950170-23-073585:0
Canonical exit: 25 Mar 2024 (T+90)
76,384 shares@ US$12.849810.3% of flowCommon StockSEC:0000950170-23-069397:0
Canonical exit: 6 Mar 2024 (T+90)
235 shares@ US$12.500.0% of flowCommon StockSEC:0000950170-23-065235:0
Canonical exit: 15 Feb 2024 (T+90)
39,283 shares@ US$12.505.2% of flowCommon StockSEC:0000950170-23-064564:0
Canonical exit: 12 Feb 2024 (T+90)
8,259 shares@ US$12.32221.1% of flowCommon StockSEC:0000950170-23-063800:1
Canonical exit: 8 Feb 2024 (T+90)
12,191 shares@ US$12.38761.6% of flowCommon StockSEC:0000950170-23-063800:2
Canonical exit: 11 Feb 2024 (T+90)
3,379 shares@ US$12.38760.4% of flowCommon StockSEC:0000950170-23-063800:3
Canonical exit: 11 Feb 2024 (T+90)
29,803 shares@ US$12.32223.9% of flowCommon StockSEC:0000950170-23-063800:0
Canonical exit: 8 Feb 2024 (T+90)
4,783 shares@ US$12.1320.6% of flowCommon StockSEC:0000950170-23-062911:0
Canonical exit: 6 Feb 2024 (T+90)
2,000 shares@ US$12.51965.0% of flowCommon StockSEC:0000950170-23-042384:0
Canonical exit: 8 Nov 2023 (T+90)
84,636 shares@ US$12.003710.4% of flowCommon StockSEC:0000950170-23-040559:0
Canonical exit: 5 Nov 2023 (T+90)
127,409 shares@ US$11.5215.5% of flowCommon StockSEC:0000950170-23-009171:0
Canonical exit: 19 Jun 2023 (T+90)
19,750 shares@ US$11.35762.3% of flowCommon StockSEC:0000899243-23-006607:0
Canonical exit: 30 Apr 2023 (T+90)
19,750 shares@ US$11.35762.3% of flowCommon StockSEC:0000899243-23-003115:0
Canonical exit: 30 Apr 2023 (T+90)
17,465 shares@ US$11.39652.1% of flowCommon StockSEC:0000899243-23-003033:0
Canonical exit: 27 Apr 2023 (T+90)
4,410 shares@ US$11.39650.5% of flowCommon StockSEC:0000899243-23-003033:1
Canonical exit: 27 Apr 2023 (T+90)
100,000 shares@ US$11.9072.9% of flowCommon StockSEC:0000899243-23-001838:0
Canonical exit: 12 Apr 2023 (T+90)
4,156 shares@ US$12.03100.0% of flowCommon StockSEC:0000899243-23-001290:0
Canonical exit: 6 Apr 2023 (T+90)
1,300 shares@ US$11.24230.9% of flowCommon StockSEC:0000899243-23-000580:0
Canonical exit: 30 Mar 2023 (T+90)
22,413 shares@ US$11.33322.7% of flowCommon StockSEC:0000899243-23-000581:0
Canonical exit: 3 Apr 2023 (T+90)
33,030 shares@ US$11.33274.0% of flowCommon StockSEC:0000899243-23-000225:2
Canonical exit: 30 Mar 2023 (T+90)
8,270 shares@ US$11.33271.0% of flowCommon StockSEC:0000899243-23-000225:3
Canonical exit: 30 Mar 2023 (T+90)
189,975 shares@ US$10.550321.3% of flowCommon StockSEC:0000899243-23-000225:0
Canonical exit: 29 Mar 2023 (T+90)
28,661 shares@ US$10.55033.2% of flowCommon StockSEC:0000899243-23-000225:1
Canonical exit: 29 Mar 2023 (T+90)
3,095 shares@ US$5.88911.2% of flowCommon StockSEC:0000899243-22-026124:0
Canonical exit: 11 Oct 2022 (T+90)
25 of 63 declarations
关于 Merrimack Pharmaceuticals INC
Merrimack Pharmaceuticals Inc. 是一家在美国纳斯达克市场上市的美国生物制药公司。该公司于 2000 年由麻省理工学院/哈佛生态系统的科学家在马萨诸塞州剑桥成立，最初以肿瘤学研究而闻名，特别是将治疗方法与诊断相结合的精准医疗方法。其总部位于美国核心生物技术中心之一的马萨诸塞州剑桥市。（[en.wikipedia.org](https://en.wikipedia.org/wiki/Merrimack_Pharmaceuticals?utm_source=openai)） 历史上，Merrimack 开发了针对实体瘤的癌症药物候选物，并推进了一个以靶向疾病机制和定制疗法为中心的平台。其最著名的资产是 ONIVYDE，一种用于肿瘤学的脂质体伊立替康产品。Merrimack 于 2017 年将其商业业务（包括 ONIVYDE）出售给 Ipsen。此后，该公司不再作为一家拥有广泛产品线的传统开发阶段生物技术公司运营；相反，其商业模式日益演变为保留与出售给第三方的资产的商业和监管表现相关的或有里程碑付款的权利。美国证券交易委员会的文件还提及了与转让给 Elevation Oncology 的资产相关的遗留合作权利。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1274792/000095017023007063/mack-20221231.htm?utm_source=openai)） 从竞争角度来看，Merrimack 占据了一个不寻常的利基市场。它不再是一家在大型临床产品线上直接竞争的多元化药物开发商；相反，它最好被视为一个剩余资产持有者，面临里程碑收款、特许权使用费和其他或有付款。这种结构降低了持续的研发强度，但也使得投资案例高度依赖事件驱动，并取决于离散的监管或商业触发因素。在最近的披露中，管理层表示，根据剩余协议获得额外里程碑付款的可能性不大，这突显了该业务的成熟和逐步终止的性质。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1274792/000119312524078910/d817534dex991.htm?utm_source=openai)） 2024 年 3 月发生了一项重大进展，Merrimack 在 ONIVYDE 获得 FDA 批准用于新的晚期胰腺癌一线适应症后，从 Ipsen 收到了 225 亿美元的里程碑付款。此后不久，该公司宣布了清算计划和向股东派发清算股息的计划，但需经股东批准。对于关注美国证券交易委员会 4 号表格内部人交易的国际投资者而言，MACK 不应被视为一家成长型生物技术公司，而应更多地被视为一个特殊情况的股权故事，其核心是最终资产变现、剩余或有付款以及遗留肿瘤学特许经营权的有序清算。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1274792/000119312524033761/d750746dex991.htm?utm_source=openai)）
